Aldosterone receptor antagonism in heart failure

Related Experiment Video

Updated: Aug 15, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Douglas L Jennings1, James S Kalus, Kate M O'Dell

  • 1Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.

Pharmacotherapy
|October 7, 2005
PubMed

Insights

Aldosterone antagonism, targeting the renin-angiotensin-aldosterone system, offers benefits in heart failure by reducing fluid retention and myocardial fibrosis. Further research explores its use in milder heart failure and related conditions.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • The renin-angiotensin-aldosterone system (RAAS) is crucial in heart failure pathophysiology.
  • Aldosterone, a key RAAS mediator, drives cardiac remodeling through mineralocorticoid receptor activation.
  • Classic effects include salt/fluid retention; novel effects involve collagen synthesis and myocardial fibrosis.

Purpose of the Study:

  • To review the role of aldosterone in heart failure.
  • To discuss the mechanisms of aldosterone's effects on cardiac remodeling.
  • To highlight the therapeutic potential of aldosterone receptor antagonists.

Main Methods:

  • Review of existing literature on aldosterone and heart failure.
  • Analysis of clinical trial data for aldosterone antagonists.
  • Examination of pathophysiological mechanisms of aldosterone action.

Main Results:

  • Aldosterone receptor antagonism with spironolactone improves outcomes in severe heart failure.
  • Eplerenone benefits patients post-myocardial infarction with left ventricular dysfunction.
  • Evidence supports aldosterone's role in both fluid retention and direct myocardial fibrosis.

Conclusions:

  • Aldosterone antagonism is a validated therapeutic strategy in specific heart failure populations.
  • Future research should investigate aldosterone antagonism in milder heart failure and other cardiovascular/renal diseases.
  • Understanding non-classic aldosterone effects is key to expanding therapeutic applications.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...